Vivos Therapeutics Creates New Series A Preferred Stock
I'm LongbridgeAI, I can summarize articles.Vivos Therapeutics raised approximately $2.1 million via a private placement of Series A Convertible Preferred Stock and warrants on June 30, 2026. The deal includes new cash and converted bridge notes, creating a new preferred stock class to strengthen liquidity while adhering to Nasdaq rules. Analysts maintain a 'Buy' rating with a $3.10 target, though AI analysis rates the stock 'Neutral' due to weak financial fundamentals and execution risks.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Vivos Therapeutics ( (VVOS) ) has shared an announcement.
On June 30, 2026, Vivos Therapeutics raised approximately $2.1 million through a private investment in public equity, selling 3.61 million units of Series A Convertible Preferred Stock and accompanying warrants to existing investors, including an affiliate tied to CEO R. Kirk Huntsman, with $1 million in new cash and $1 million from a prior bridge note converting into the deal. The financing, structured to meet Nasdaq pricing rules and limit individual ownership levels, and the July 7, 2026 creation of a new 7.5 million-share Series A Convertible Preferred Stock class with fixed one-for-one convertibility, strengthens the company’s liquidity while setting clear anti-dilution, control, and liquidation preference terms that shape future dilution and governance dynamics for current shareholders.
The new preferred shares carry no fixed dividend, limited voting rights focused on protecting preferred holders, and conversion caps at up to 19.99% ownership, while the five-year warrants are immediately exercisable at $0.456 per share. Together, these instruments provide Vivos with flexible growth capital for working capital needs but also introduce potential future share overhang, as the company must register underlying common shares for resale and manage ongoing investor protections and ownership limits.
The most recent analyst rating on (VVOS) stock is a Buy
with a $3.10 price target.
To see the full list of analyst forecasts on Vivos Therapeutics stock,
see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
The score is primarily constrained by weak financial fundamentals—large losses, heavy cash burn, and negative equity—despite improving revenue and gross margin. Technicals add further pressure given the pronounced downtrend versus major moving averages. Earnings-call commentary and corporate actions show credible growth initiatives and restructuring efforts, but near-term funding and execution risk remains significant.
To see Spark’s full report on VVOS stock,
click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc., a Delaware corporation listed on Nasdaq, operates in the medical technology and therapeutics space, focusing on products and treatments related to dental and airway health. The company raises capital periodically through equity and equity-linked securities to fund general working capital and support ongoing operations in its niche healthcare market.
Average Trading Volume: 1,706,268
Technical Sentiment Signal: Sell
Current Market Cap: $6.3M